PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability

• Main Authors: Jiaojiao Yu (Author), Yujin Xiang (Author), Yuzhen Gao (Author), Shan Chang (Author), Ren Kong (Author), Xiaoxi Lv (Author), Jinmei Yu (Author), Yunjie Jin (Author), Chenxi Li (Author), Yiran Ma (Author), Zhenhe Wang (Author), Jichao Zhou (Author), Hongyu Yuan (Author), Shuang Shang (Author), Fang Hua (Author), Xiaowei Zhang (Author), Bing Cui (Author), Pingping Li (Author)
• Format: Book
• Published: Elsevier, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Protein kinase C α (PKCα) regulates diverse biological functions of cancer cells and is a promising therapeutic target. However, clinical trials of PKC-targeted therapies have not yielded satisfactory results. Recent studies have also indicated a tumor-suppressive role of PKCs via unclear molecular...